Fertility after Curative Therapy for Sickle Cell Disease: A Comprehensive Review to Guide Care. [Review] 

 -  2022 
<br/><br/> Curative therapy for sickle cell disease (SCD) currently requires gonadotoxic conditioning that can impair future fertility. Fertility outcomes after curative therapy are likely affected by pre-transplant ovarian reserve or semen analysis parameters that may already be abnormal from SCD-related damage or hydroxyurea treatment. Outcomes are also likely affected by the conditioning regimen. Conditioning with myeloablative busulfan and cyclophosphamide causes serious gonadotoxicity particularly among post-pubertal females. Reduced-intensity and non-myeloablative conditioning may be acutely less gonadotoxic, but more short and long-term fertility outcome data after these approaches is needed. Fertility preservation including oocyte/embryo, ovarian tissue, sperm, and experimental testicular tissue cryopreservation should be offered to patients with SCD pursing curative therapy. Regardless of HSCT outcome, longitudinal post-HSCT fertility care is required. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>2077-0383 
<br/><br/><label>Standard No.: </label>10.3390/jcm11092318 [doi] jcm11092318 [pii] PMC9105328 [pmc] 
<br/><br/><label>Index Terms--Occupation: </label><br/>MedStar Georgetown University Hospital/MedStar Washington Hospital Center<br/>Urology Residency-Advanced
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article<br/>Review